Listing of adverse events (AEs) by systems organ class (SOC) and preferred term (PT)
| SOC/PT | Total population (N=876) |
| All AEs | |
| Patients with at least one AE | 43 (4.9%) |
| Total number of AEs | 67 |
| Cardiac disorders | |
| Angina pectoris | 2 (0.2%) |
| Atrial fibrillation | 1 (0.1%) |
| Mitral valve incompetence | 1 (0.1%) |
| Tricuspid valve incompetence | 1 (0.1%) |
| Gastrointestinal disorders | |
| Abdominal distension | 1 (0.1%) |
| Abdominal pain | 2 (0.2%) |
| Gastritis | 1 (0.1%) |
| Gastrointestinal motility disorder | 1 (0.1%) |
| Nausea | 15 (1.6%) |
| Toothache | 1 (0.1%) |
| Vomiting | 3 (0.3%) |
| Intestinal transit time increased | 1 (0.1%) |
| General disorders and administration site conditions | |
| Asthenia | 1 (0.1%) |
| Chest discomfort | 1 (0.1%) |
| Injection site hypersensitivity | 1 (0.1%) |
| Injection site urticaria | 1 (0.1%) |
| Infections and infestations | |
| Cellulitis | 1 (0.1%) |
| Diabetic gangrene | 1 (0.1%) |
| Gangrene | 1 (0.1%) |
| Nasopharyngitis | 1 (0.1%) |
| Pharyngotonsillitis | 1 (0.1%) |
| Tooth infection | 1 (0.1%) |
| Upper respiratory tract infection | 2 (0.2%) |
| Metabolism and nutrition disorders | |
| Decreased appetite | 1 (0.1%) |
| Hypoglycaemia | 13 (1.5%) |
| Hypomagnesaemia | 1 (0.1%) |
| Musculoskeletal and connective tissue disorders | |
| Exostosis | 1 (0.1%) |
| Nervous system disorders | |
| Diabetic neuropathy | 1 (0.1%) |
| Dizziness | 2 (0.2%) |
| Headache | 4 (0.5%) |
| Respiratory, thoracic and mediastinal disorders | |
| Pneumothorax | 1 (0.1%) |
| Vascular disorders | |
| Peripheral arterial occlusive disease | 1 (0.1%) |